Buy Omnicell Stock in 2026: Share Price, Dividend and Analysis

Looking to buy Omnicell stock (OMCL)? This US company equips hospitals and pharmacies with medication automation systems: smart cabinets, dispensing robots and medication management software. This profile brings together a company overview, results for the last three financial years, dividend policy, strengths and risks, and then a practical method for buying the stock from France.

The case reads like a cyclical healthcare technology stock: a solid niche and recurring revenue, but profitability that is still fragile and a valuation that follows healthcare system budgets.

Omnicell Stock Price

The live OMCL quote is available from your broker or on the leading financial platforms; trading hours are covered below.

Omnicell Stock Profile

CompanyOmnicell, Inc.
MarketNASDAQ (New York) (checked on November 10, 2026)
Ticker / SymbolOMCL
ISINUS68213N1090
HeadquartersFort Worth, Texas (United States)
SectorHealthcare technology: medication management automation (hospitals, pharmacies)
Trading currencyUS dollar (USD)
Financial year endDecember 31
PEA eligibilityNo (issuer domiciled outside the EU/EEA: United States)

About Omnicell

Automating the medication process

Omnicell equips the medication supply chain: in hospitals, connected cabinets dispense treatments at the patient’s bedside and track every dose; in retail pharmacies, packaging and verification systems automate prescription preparation. The software that links this equipment to patient records is the group’s growing layer of value.

A two-segment model with recurring revenue

The group sells equipment but mainly lives off services: consumables, maintenance and software licences. This recurring share provides welcome visibility, but equipment sales remain cyclical: they follow the capital budgets of hospitals and pharmacy chains, which are highly sensitive to funding conditions in US healthcare.

Profitability being rebuilt

Recent years have been tough: slowing equipment orders, high overheads and sharply weaker results, followed by a gradual rebuilding of profitability. The case now hinges on management’s ability to bring costs down faster than equipment sales decline, while developing the software platform.

Omnicell Results and Financial Data

Consolidated accounts for the last three financial years ended December 31:

IndicatorFY 2023FY 2024FY 2025Year-on-year change
Revenue$1,147.1M$1,112.2M$1,184.8M+6.5%
Net income-$20.4M$12.5M$2.1M-83.2%

Source: S&P Global Market Intelligence via StockAnalysis, consolidated accounts; data accessed on November 10, 2026.

The sequence is instructive: after the business slump of 2024, revenue rebounded by 6.5% in 2025, but profitability remains razor-thin — net income of $2.1 million on nearly $1.2 billion in sales, a margin close to zero. The case is still a story of margin recovery, not yet a profitable growth stock.

Tableau originalDiversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

Omnicell Stock Dividend

Omnicell does not pay a dividend: the company uses its cash flow to fund its products, its sales force and its debt. There is no current yield on this stock.

Investors can only aim for share price growth, in a stock whose profitability remains fragile — a profile in which your entry price and position sizing matter twice as much.

Should You Buy Omnicell Stock in 2026?

Strengths:

  • A defensible technology niche: automating the medication process in hospitals.
  • A revenue rebound in 2025 (+6.5%) and a solid base of recurring revenue.
  • A structural theme: the shortage of healthcare staff is driving automation.

Points to watch:

  • Near-zero profitability in 2025: margins are what the bet is about, not a given.
  • Highly cyclical equipment sales to healthcare systems.
  • Competition from large medical equipment makers and pressure on hospital budgets.
  • No dividend: returns depend entirely on the share price.

Omnicell is a healthcare technology turnaround stock: the niche is real and the commercial rebound is there, but lasting profitability has yet to be proven. The position should be sized as a moderate conviction holding, with a patient entry point and margins monitored at every release — the execution rules are in our guide to buying shares. To widen the comparison to the sector, see our selection of the best healthcare stocks.

Fundamental and Technical Analysis of Omnicell Stock

Fundamental analysis

Three indicators drive the case: the share and growth of recurring revenue (services, software, consumables), operating margin — the real focus of the turnaround — and the debt structure inherited from the expansion years. The 2025 sales rebound is a signal; without restored margins, it is not enough.

Technical analysis

The stock reacts strongly to quarterly releases, especially equipment orders and annual guidance. The 12-month high and low levels, as well as long-term moving averages, serve as reference points; volatility around results regularly exceeds 5% intraday, which rules out leveraged trading on this name.

How to Buy Omnicell Stock

  1. Choose a broker that gives access to the NASDAQ; compare fees in our selection of the best stock brokers.
  2. Open an ordinary securities account (US stocks are excluded from the PEA, see our PEA page) and verify your identity.
  3. Fund the account, taking euro-dollar conversion fees into account.
  4. Place a limit order on the OMCL ticker, avoiding earnings release windows.

Trading hours

The NASDAQ trades from 9:30 a.m. to 4:00 p.m. New York time, which is usually 3:30 p.m. to 10:00 p.m. in Paris. Shares can be bought one at a time.

Taxation

Capital gains are subject to the French 30% flat tax (PFU) in a securities account. As no dividend is paid, taxation is limited to capital gains.

Frequently Asked Questions About Omnicell Stock

Which exchange is Omnicell stock listed on?

On the NASDAQ in New York, under the symbol OMCL, in US dollars.

Does Omnicell pay a dividend?

No. The company reinvests its cash flow in its development and in its debt.

Can you hold OMCL in a PEA?

No. US stocks are excluded from the PEA: the stock is held in an ordinary securities account.

What is Omnicell’s ISIN code?

US68213N1090.

What were Omnicell’s 2025 results?

Revenue of around $1.18 billion (+6.5%) and net income of $2.1 million, according to the consolidated accounts.

Disclaimer: this content is for information only and does not constitute investment advice. Investing in the stock market carries a risk of capital loss; past performance is not a reliable indicator of future performance.

Suivez-nous sur Telegram